Business context and reporting period
The supplied filing is AcelRx Pharmaceuticals, Inc.’s Form 10-Q for the quarter ended September 30, 2017—not a Talphera, Inc. filing as indicated in the request metadata. AcelRx develops acute-pain therapies, including DSUVIA/ARX-04 and ZALVISO. Financial statements are unaudited.
Financial performance and position
Amounts below are in millions of dollars, except per-share data.
| Metric | Q3 2017 | Q3 2016 | Nine months 2017 | Nine months 2016 |
|---|---|---|---|---|
| Total revenue | 1.5 | 3.4 | 7.3 | 10.9 |
| Cost of goods sold | 2.0 | 2.6 | 9.7 | 9.2 |
| Operating loss | (8.9) | (8.0) | (30.9) | (24.8) |
| Net loss | (13.0) | (11.4) | (41.6) | (33.5) |
| Net loss per share, basic and diluted | (0.28) | (0.25) | (0.91) | (0.74) |
| Cash used in operating activities | Not presented quarterly | (23.1) | (19.1) |
Revenue comprised collaboration revenue of $1.2 million in Q3 and $6.4 million year to date, and contract and other revenue of $0.3 million and $0.8 million, respectively. ZALVISO product sales under the Grunenthal collaboration contributed $1.1 million in Q3 and $6.0 million year to date. Cost of goods sold exceeded total revenue in both reported 2017 periods; management anticipated negative gross margins on ZALVISO deliveries for the foreseeable future.
At September 30, cash and cash equivalents were $67.9 million, down from $80.3 million at December 31, 2016. Current assets were $71.1 million and current liabilities $14.9 million. Balance-sheet debt was approximately $22.4 million ($9.3 million current and $13.2 million long-term); the filing also reports an accrued Hercules balance of $22.4 million. The liability related to the sale of future royalties was $80.8 million, including $0.5 million current. Stockholders’ deficit was $30.3 million. The company raised $13.1 million net through its at-the-market stock program during the first nine months.
Material changes versus the prior comparable period
- Q3 revenue fell $1.9 million year over year, and nine-month revenue fell $3.7 million, mainly reflecting lower Department of Defense contract revenue. Collaboration revenue increased year to date, but did not offset that decline.
- Net loss widened by $1.6 million in Q3 and $8.1 million year to date. Nine-month operating expenses rose to $38.1 million from $35.7 million; interest and other expense also increased.
- Operating cash use rose $4.0 million year to date. Cash declined despite $13.1 million of net equity proceeds.
- On March 2, 2017, AcelRx refinanced its Hercules borrowing. The new loan has a scheduled March 2020 maturity, subject to extension conditions, and carries interest at a minimum 9.55% under the stated formula. Principal and interest payments were scheduled to begin after the interest-only period.
Outlook, risks, and unusual items
- DSUVIA: On October 12, 2017, after quarter-end, the FDA issued a Complete Response Letter stating it could not approve the NDA in its current form. The FDA requested additional safety data from at least 50 patients at the proposed maximum dose and revisions to use instructions addressing errors, including dropped tablets, validated in a Human Factors study. AcelRx requested a Type A meeting; the resubmission timetable and required work were not yet established.
- ZALVISO: Management remained on track to resubmit its U.S. NDA by year-end 2017, after the DSUVIA FDA meeting. The IAP312 study reported a 2.2% device-error rate, below its 5% study limit; FDA acceptance of the results was not assured. ZALVISO was approved and launched in several European countries, but European royalties were expected to be minimal in 2017.
- ARX-04 in Europe: EMA scientific review was underway, with a CHMP opinion expected in the first half of 2018. Additional studies could be needed for a trauma-pain label or reimbursement in some countries.
- Liquidity: Management expected available capital to fund operations through at least the end of 2018. This estimate was subject to change, particularly as the scope and cost of DSUVIA CRL work remained uncertain. The company expected continuing losses and negative operating cash flows and stated additional capital would eventually be needed; financing might not be available on acceptable terms.
- Royalty monetization: The PDL-related liability is accounted for as financing and accrues non-cash interest using an estimated effective annual rate of about 14%. AcelRx anticipated approximately $11 million of this non-cash interest expense for 2017. Actual timing and amount of royalty receipts could change the estimate.
- Other risks and items: AcelRx recorded a $0.4 million inventory impairment, primarily related to ZALVISO materials and commitments. It identified manufacturing concentration and supply risks, potential negative ZALVISO margins, regulatory uncertainty, opioid-related restrictions, and financing/dilution risks. No material legal proceedings were reported. Management concluded disclosure controls were effective and reported no material internal-control changes in the quarter.
Most important facts for investors to verify
- Confirm issuer identity: the provided 10-Q names AcelRx Pharmaceuticals, Inc., not Talphera, Inc.
- Follow the FDA meeting, additional data and Human Factors requirements, costs, and timing for DSUVIA resubmission.
- Verify the status and FDA response to the planned ZALVISO NDA resubmission, including any further device or safety requirements.
- Track cash burn, financing needs, Hercules debt terms and payments, and progress toward any loan-extension liquidity milestone.
- Assess ZALVISO European demand, transfer-price economics, supply costs, and the effect of the PDL royalty-sharing arrangement on cash receipts.